Verapamil and Its Role in Diabetes

Zimmermann, Paul; Aberer, Felix; Eckstein, Max L.; Haupt, Sandra; Erlmann, Maximilian P.; Moser, Othmar

doi:10.3390/diabetology3030030

Cited by 2 publications

(2 citation statements)

References 67 publications

(151 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, since the loss of functional β-cell mass is one of the critical aspects, various therapeutic approaches have been developed in recent decades to prevent or slow down this process [ 55 ]. To preserve β-cell mass, and replace endogenous insulin, exogenous insulin is used as the primary treatment for all people with T1DM [ 56 ]. Whilst conventional therapy existing of fixed-dose regimens was standard practice in the past and can still be used in certain circumstances, it is generally not the preferred option [ 57 ].…”

Section: Impact Of Fasting As An Adjuvant Therapy In T1dm and T2dmmentioning

confidence: 99%

Efficacy of Fasting in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review

et al. 2023

Self Cite

View full text Add to dashboard Cite

Over the last decade, studies suggested that dietary behavior modification, including fasting, can improve metabolic and cardiovascular markers as well as body composition. Given the increasing prevalence of people with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) and the increasing obesity (also in combination with diabetes), nutritional therapies are gaining importance, besides pharmaceutical interventions. Fasting has demonstrated beneficial effects for both healthy individuals and those with metabolic diseases, leading to increased research interest in its impact on glycemia and associated short- and long-term complications. Therefore, this review aimed to investigate whether fasting can be used safely and effectively in addition to medications to support the therapy in T1DM and T2DM. A literature search on fasting and its interaction with diabetes was conducted via PubMed in September 2022. Fasting has the potential to minimize the risk of hypoglycemia in T1DM, lower glycaemic variability, and improve fat metabolism in T1DM and T2DM. It also increases insulin sensitivity, reduces endogenous glucose production in diabetes, lowers body weight, and improves body composition. To conclude, fasting is efficient for therapy management for both people with T1DM and T2DM and can be safely performed, when necessary, with the support of health care professionals.

show abstract

Section: Impact Of Fasting As An Adjuvant Therapy In T1dm and T2dmmentioning

confidence: 99%

Efficacy of Fasting in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Of note, calcium plays a central role in cytokine action as well as in the mitochondrial death pathway related to the mitochondrial permeability transition pore [21,22], which may or may not be directly linked with the effects of verapamil on TXNIP. For additional reading, a review by Zimmerman et al provides a detailed description of verapamil with regard to calcium, TXNIP action, and diabetes [23].…”

Section: Verapamilmentioning

confidence: 99%

Emerging Anti-Diabetic Drugs for Beta-Cell Protection in Type 1 Diabetes

Ajmal

Bogart

Khan

et al. 2023

Cells

View full text Add to dashboard Cite

Type 1 diabetes (T1D) is a chronic autoimmune disorder that damages beta cells in the pancreatic islets of Langerhans and results in hyperglycemia due to the loss of insulin. Exogenous insulin therapy can save lives but does not halt disease progression. Thus, an effective therapy may require beta-cell restoration and suppression of the autoimmune response. However, currently, there are no treatment options available that can halt T1D. Within the National Clinical Trial (NCT) database, a vast majority of over 3000 trials to treat T1D are devoted to insulin therapy. This review focuses on non-insulin pharmacological therapies. Many investigational new drugs fall under the category of immunomodulators, such as the recently FDA-approved CD-3 monoclonal antibody teplizumab. Four intriguing candidate drugs fall outside the category of immunomodulators, which are the focus of this review. Specifically, we discuss several non-immunomodulators that may have more direct action on beta cells, such as verapamil (a voltage-dependent calcium channel blocker), gamma aminobutyric acid (GABA, a major neurotransmitter with effects on beta cells), tauroursodeoxycholic acid (TUDCA, an endoplasmic reticulum chaperone), and volagidemab (a glucagon receptor antagonist). These emerging anti-diabetic drugs are expected to provide promising results in both beta-cell restoration and in suppressing cytokine-derived inflammation.

show abstract

Verapamil and Its Role in Diabetes

Cited by 2 publications

References 67 publications

Efficacy of Fasting in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review

Efficacy of Fasting in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review

Emerging Anti-Diabetic Drugs for Beta-Cell Protection in Type 1 Diabetes

Contact Info

Product

Resources

About